NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22) - Clinical Trial Not Allowed
The summary for the NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22) - Clinical Trial Not Allowed grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22) - Clinical Trial Not Allowed: The NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity is designed to enhance the participation of highly trained early career investigators from diverse backgrounds underrepresented in neuroscience research. This opportunity provides individuals from diverse backgrounds with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position. Individuals from diverse backgrounds underrepresented in neuroscience research are eligible for support under this award if they have doctoral research degrees (Ph.D., Ph.D./M.D. or equivalent) and between 2 and 5 years of postdoctoral prior research training at the time of application. The primary objectives of this Funding Opportunity Announcement (FOA) are to: (1) assist talented scientists from underrepresented groups to transition from postdoctoral training to a secure, independent research position and (2) enhance the conditions that promote establishing a strong and innovative independent program of research.
Federal Grant Title: | NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22) - Clinical Trial Not Allowed |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Health |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-18-469 |
Type of Funding: | Grant |
CFDA Numbers: | 93.853 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | January 7th, 2021 |
Original Application Deadline: | January 7th, 2021 |
Posted Date: | December 4th, 2017 |
Creation Date: | December 4th, 2017 |
Archive Date: | February 12th, 2021 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | December 4th, 2017 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-18-469.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...
- • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...
- • Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contribution...
- • Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging fin...
- • NINDS Program Project Grant (P01 Clinical Trial Optional)
- • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44)
- • NINDS Institutional Center Core Grants to Support Neuroscience Research
- • Career Development Award to Promote Diversity in Neuroscience Research
- More Grants from the National Institutes of Health
- • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...
- • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...
- • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...
- • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
- • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...